Your browser doesn't support javascript.
loading
Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer.
Inoue, Akira; Robinson, Frederick S; Minelli, Rosalba; Tomihara, Hideo; Rizi, Bahar Salimian; Rose, Johnathon L; Kodama, Takahiro; Srinivasan, Sanjana; Harris, Angela L; Zuniga, Andy M; Mullinax, Robert A; Ma, Xiaoyan; Seth, Sahil; Daniele, Joseph R; Peoples, Michael D; Loponte, Sara; Akdemir, Kadir C; Khor, Tin Oo; Feng, Ningping; Roszik, Jason; Sobieski, Mary M; Brunell, David; Stephan, Clifford; Giuliani, Virginia; Deem, Angela K; Shingu, Takashi; Deribe, Yonathan Lissanu; Menter, David G; Heffernan, Timothy P; Viale, Andrea; Bristow, Christopher A; Kopetz, Scott; Draetta, Giulio F; Genovese, Giannicola; Carugo, Alessandro.
  • Inoue A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Gastroenterological Surgery, Osaka General Medical Center, Osaka, Japan. Electronic address: inoue_akira@gh.opho.jp.
  • Robinson FS; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Minelli R; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tomihara H; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rizi BS; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rose JL; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kodama T; Department of Gastroenterology and Hepatology, Graduate School of Medicine, Osaka University, Osaka, Japan.
  • Srinivasan S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Harris AL; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Zuniga AM; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mullinax RA; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ma X; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Seth S; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Daniele JR; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Peoples MD; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Loponte S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Akdemir KC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Khor TO; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Feng N; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Roszik J; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sobieski MM; Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas.
  • Brunell D; Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas.
  • Stephan C; Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas.
  • Giuliani V; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Deem AK; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shingu T; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Deribe YL; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Menter DG; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Heffernan TP; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Viale A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bristow CA; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kopetz S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Draetta GF; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Genovese G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: ggenovese@mdanderson.org.
  • Carugo A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: acarugo@mdanderson.
Gastroenterology ; 161(1): 196-210, 2021 07.
Article en En | MEDLINE | ID: mdl-33745946
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Proteína p53 Supresora de Tumor / Receptores Citoplasmáticos y Nucleares / Carioferinas / Inhibidores de Proteínas Quinasas / Proteínas de la Ataxia Telangiectasia Mutada / Mutación Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Proteína p53 Supresora de Tumor / Receptores Citoplasmáticos y Nucleares / Carioferinas / Inhibidores de Proteínas Quinasas / Proteínas de la Ataxia Telangiectasia Mutada / Mutación Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2021 Tipo del documento: Article